Kidney Precision Medicine Program (KPMP): Columbia AKI Recruitment Site

肾脏精准医学计划 (KPMP)：哥伦比亚 AKI 招聘网站

基本信息

批准号：
9911000
负责人：
JONATHAN M. BARASCH
金额：
$ 30万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-15 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9911000
关键词：
Academic Medical Centers Acute Renal Failure with Renal Papillary Necrosis Address Adult Affect African American Area Basic Science Biological Markers Biopsy Biopsy Specimen Blood Blood Cells Cardiovascular system Cells Chronic Kidney Failure Clinical Clinical Data Clinical Sciences Collaborations Collection Communities Complement Computerized Medical Record Consensus Consult Core Biopsy Coupled Couples Critical Pathways Data Data Collection Diagnosis Diagnostic Electronic Health Record Enrollment Ensure Epidemiology Etiology Event Feces Foundations Functional disorder Genetic Genetic Markers Genetic Processes Goals Gold Histopathology Hypertension Injury Injury to Kidney Inpatients Kidney Kidney Diseases LCN2 gene Latino Life Longitudinal Studies Longitudinal cohort Measurement Measures Medical Medical Genetics Methods Molecular Morbidity - disease rate Nephrology Nephrons New York Outcome Participant Patients Persons Phase Plasma Protocols documentation Renal Mass Renal function Research Research Personnel Resources Response to stimulus physiology Risk Risk Factors Role Route Saliva Scientist Sepsis Serum Services Site Solid Standardization Stimulus Surveys Techniques Technology Testing Therapeutic Time Time trend Tissues To specify Uncertainty Universities Urine Visit Work base cohort diagnosis standard effective therapy expectation experience follow-up genomic biomarker genomic data global health interest kidney biopsy metropolitan microbiome research mortality multidisciplinary nephrotoxicity novel patient engagement precision medicine programs prospective recruit renal damage response response to injury targeted treatment

项目摘要

Project Summary (Abstract) Our project brings together an experienced multidisciplinary team of clinical and basic scientist investigators at Columbia University Medical Center with expertise in the fields of genetics, biomarkers, pathophysiology, histopathology, renal biopsies, and therapy for kidney diseases to meet the aims of the Kidney Precision Medicine Project (KPMP) Recruitment Site for acute kidney injury (AKI). Our primary objective in establishing this site is to apply precision medicine techniques to patient biospecimens, including renal biopsies, and longitudinal clinical data to understand the etiology of kidney damage and determine critical pathways that can be targeted for therapy. The KPMP will occur in two phases: the UG3 exploratory phase and the UH3 expansion phase. Leveraging our existing inpatient nephrology consult services, we will create a multiethnic cohort (including >50% enrollment of Latino and/or African-American subjects) of at least 200 patients with AKI over five years. In the exploratory phase of the project, we will enroll at least 50 subjects over two years and will standardize the collection of biospecimens from all study participants including blood, saliva, urine, stool, and renal biopsy samples collected specifically for research purposes. The biospecimens will be pre-processed for genetic, genomic, biomarker, and microbiome studies before the material is transferred to the KPMP Central Hub. To track patient progress and outcomes, a longitudinal study protocol will be used consisting of “dynamic” follow-up visits through electronic health records and yearly in-person visits. In addition, we will share all extracted electronic health record data, survey data, and longitudinal clinical data from follow-up visits from our participants with the larger KPMP initiative for collaborative purposes. In the expansion phase, we will increase the cohort size by enrolling an additional 150 patients over three years and use KPMP consortium- wide established protocols from the exploratory phase for biospecimen collection and longitudinal clinical data collection. We will perform proof-of-concept studies with the longitudinal cohort of 200 Columbia patients with AKI to determine a standard set of outcomes based on risk factors, known serum biomarkers, and genomic data. Lastly, we will work with local kidney foundation chapters and community engagement experts to ensure that the aims of the national KPMP are shared with the larger community so that participants understand the importance of this initiative and the long-term benefits of continued study involvement. We expect that this novel, tissue-based, mechanism-centered approach will challenge the traditional methods for diagnosing and treating AKI and will contribute to the overall goals of the national KPMP.

项目概要（摘要）我们的项目汇集了一支经验丰富的多学科团队，由临床和基础科学家研究人员组成哥伦比亚大学医学中心拥有遗传学、生物标志物、病理生理学等领域的专业知识，组织病理学、肾活检和肾脏疾病治疗，以实现肾脏精准的目标急性肾损伤 (AKI) 医学项目 (KPMP) 招募网站我们的主要目标是建立。该网站旨在将精准医学技术应用于患者生物样本，包括肾活检，以及纵向临床数据，以了解肾脏损伤的病因并确定可治疗的关键途径 KPMP 将分两个阶段进行：UG3 探索阶段和 UH3 阶段。利用我们现有的住院肾脏病咨询服务，我们将创建一个多种族的服务。至少 200 名 AKI 患者的队列（包括 50% 以上的拉丁裔和/或非裔美国人受试者）在该项目的探索阶段，我们将在两年内招募至少 50 名受试者。将对所有研究参与者的生物样本采集进行标准化，包括血液、唾液、尿液、粪便、专门为研究目的收集的肾活检样本将被预处理。在材料转移到 KPMP 之前进行遗传、基因组、生物标志物和微生物组研究为了跟踪患者的进展和结果，将使用纵向研究方案，其中包括：通过电子健康记录和每年的亲自访视进行“动态”随访。共享从随访中提取的所有电子健康记录数据、调查数据和纵向临床数据在扩展阶段，我们将与更大的 KPMP 计划的参与者合作。通过在三年内额外招募 150 名患者并使用 KPMP 联盟来增加队列规模从生物样本收集和纵向临床数据探索阶段开始广泛建立的协议我们将对 200 名哥伦比亚患者的纵向队列进行概念验证研究。 AKI 根据风险因素、已知血清生物标志物和基因组确定一组标准结果最后，我们将与当地肾脏基金会分会和社区参与专家合作，以确保。国家 KPMP 的目标与更大的社区共享，以便参与者了解我们期望这一举措的重要性以及持续参与研究的长期好处。新颖的、基于组织的、以机制为中心的方法将挑战传统的诊断和治疗方法治疗 AKI 并将有助于实现国家 KPMP 的总体目标。